Scarica l'app Stockscreener
18.68
0.48%
-0.09
Dopo l'orario di chiusura:
18.15
-0.53
-2.84%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
MoonLake Expects To File Sonelokimab For HS Later In 2026 - Citeline News & Insights
MoonLake touts Phase II sonelokimab results in spine disease study - FirstWord Pharma
Needham Raises MoonLake Immunotherapeutics' Price Target to $25 From $20, Buy Rating Kept - marketscreener.com
MLTX: BLA submission for SLK in HS on track, supported by robust efficacy, safety, and financial runway - TradingView
MoonLake Immunotherapeutics (MLTX) Is Up 19.0% After Positive Phase 2 Axial Spondyloarthritis Data ReleaseHas The Bull Case Changed? - simplywall.st
MLTX: BLA submission for SLK in HS on track, supported by robust efficacy and safety data - TradingView
MoonLake stock surges 63% after InvestingPro Fair Value call By Investing.com - Investing.com Australia
MoonLake's sonelokimab shows strong Phase II efficacy in axSpA, challenging UCB’s Bimzelx - European Biotechnology Magazine
Why Is MoonLake Immunotherapeutics Stock Trading Higher TodayMoonLake (NASDAQ:MLTX) - Benzinga
MoonLake stock surges on positive axSpA trial data By Investing.com - Investing.com Canada
MoonLake stock surges on positive axSpA trial data - Investing.com India
US Premarket Movers: Arcellx, Domino’s, MoonLake, Vanda, Veris - Bloomberg.com
MoonLake Highlights Positive S-OLARIS Data and Investor Day - TipRanks
MoonLake arthritis win kicks off pivotal year for IL-17 nanobody - Fierce Biotech
MoonLake Immunotherapeutics' Spine Disease Treatment Shows Improvement in a Phase 2 Study - marketscreener.com
Swiss biotech MoonLake unveils good trial results and strong cash position - Business Weekly
MLTX Stock Jumps Over 10% Overnight As Spine Drug Trial Win Sets Stage For Investor Day Showdown - Stocktwits
MoonLake announces results from Phase 2 trial of Sonelokimab - TipRanks
MoonLake reports positive phase 2 axial spondyloarthritis data By Investing.com - Investing.com Australia
MoonLake reports positive phase 2 axial spondyloarthritis data - Investing.com
MoonLake Immunotherapeutics Reports Promising Phase 2 Results for Sonelokimab in Axial Spondyloarthritis and Financial Updates - Quiver Quantitative
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results - The Manila Times
MoonLake has 'a lot of confidence' ahead of FDA submission, discloses mid-stage arthritis win - Endpoints News
Biotechnology company MoonLake Immunotherapeutics announced that its innovative drug Sonelokimab achieved positive topline results in a Phase II clinical trial for axial spondyloarthritis. - Bitget
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites - Stocktwits
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given New $12.00 Price Target at Royal Bank Of Canada - MarketBeat
RBC Raises Price Target on MoonLake Immunotherapeutics to $12 From $10, Keeps Sector Perform, Speculative Risk - marketscreener.com
Merck made $3B+ offer for MoonLake earlier this yearreport - MSN
Principal Financial Group Inc. Invests $509,000 in MoonLake Immunotherapeutics $MLTX - MarketBeat
What is the Moat Score of MoonLake ImmunotherapeuticsJuly 2025 Levels & Growth Focused Stock Reports - mfd.ru
MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week - Stocktwits
MoonLake Immunotherapeutics (MLTX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 8.5%Still a Buy? - MarketBeat
MoonLake Immunotherapeutics (MLTX) Stock Analysis: A 25% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover - MSN
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Price-Driven Insight from (MLTX) for Rule-Based Strategy - Stock Traders Daily
Will MoonLake Immunotherapeutics announce a stock splitWeekly Trade Recap & Capital Protection Trading Alerts - mfd.ru
Volume Recap: What is the cash position of MoonLake ImmunotherapeuticsWeekly Market Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
MoonLake Immunotherapeutics (MLTX) Valuation Check After Mixed Share Price Performance - Yahoo Finance
MoonLake Immunotherapeutics (NASDAQ:MLTX) Institutional Owners May Be Pleased With Recent Gains After 64% Loss Over the Past Year - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Recent Share Price Volatility - simplywall.st
Is MoonLake Immunotherapeutics stock heavily shorted2025 Momentum Check & Weekly High Return Opportunities - mfd.ru
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
BTIG Maintains Buy on MLTX (MoonLake Immunotherapeutics) Feb 2026 - Meyka
BTIG Reiterates Buy Rating for MoonLake (MLTX) with $24 Price Ta - GuruFocus
BTIG Research Reiterates "Buy" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
BTIG reiterates Buy rating on Moonlake Immunotherapeutics stock ahead of data - Investing.com India
BTIG reiterates Buy rating on Moonlake Immunotherapeutics stock ahead of data By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics: Fast-Track Sonelokimab and Multi-Indication Late-Stage Catalysts Underpin Buy Rating and $32 Target - TipRanks
MoonLake Immunotherapeutics (MLTX) Is Down 7.5% After FDA Fast Track Nod For Sonelokimab In PPP – Has The Bull Case Changed? - simplywall.st
MoonLake Finds Its Footing as FDA Wins Reset the Risk-Reward Profile - Investing.com
Two publications and an FDA fast track designation for Swiss biotechs - Startupticker.ch
(MLTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
MoonLake Immunotherapeutics (MLTX) Stock Analysis: Assessing Growth Potential with an 18% Upside - DirectorsTalk Interviews
2.25%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):